Only complete language versions are shown.
Eligible adults starting targeted therapy for ROS1-positive lung cancer or progressing after crizotinib may use taletrectinib to seek tumour response. Shanghai specialist teams involved in TRUST-I can discuss medication according to the cause of resistance, brain lesions and tolerance; patient acceptance and supply need confirmation.
Free initial service consultation · Understand your options and budget before you travel
From the 2024 single-arm phase II paper; not a superiority comparison between medicines or each patient's chance of success. View the evidence
Benefit differs between ROS1-TKI-naive patients and those previously treated with crizotinib; the US has also approved the medicine. The price entry, checked on 2026-10-03, is marked “patient-supplied” and does not establish stock or a price for foreigners. Fully self-funded without insurance or free drugs. View sources
China's TRUST-I generated experience before ROS1 treatment and after crizotinib, with participation from Shanghai specialists. Previous treatment and progression sites can inform whether taletrectinib suits the next stage.
Consider progression sites and repeat testing. Not all resistance mechanisms can be assumed sensitive; evidence after other ROS1 medicines requires separate assessment.
The study observed intracranial activity, but symptomatic brain metastases still require discussion of radiotherapy or other local treatment. Do not consider only changes in lesions elsewhere in the body.
At 600mg once daily, calculate 30-day consumption and whole-box purchases separately. Foreign patients are fully self-funded without Chinese health insurance or free drugs. A published “patient-supplied” entry does not prove stock is available to purchase.
A “patient-supplied” price entry does not establish hospital stock or that foreigners can buy at that price. Confirm the actual quote, supply and international consultation costs separately; accommodation and transport are additional.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
TRUST-I was a Chinese multicentre study; outcomes before ROS1 treatment and after crizotinib must be interpreted separately. US approval in 2025 also considered TRUST data. This drug is not exclusive to China.
Do not mix data from different follow-up versions. This study cannot guarantee efficacy after repotrectinib failure.
Explore Shanghai teams whose research and clinical focus relate to your condition and may warrant further discussion.
Key TRUST-I research team
If you wish to discuss initial treatment or options after crizotinib in Shanghai, consider the relevant Shanghai East Hospital specialty. The TRUST-I paper and official research sponsor announcements record Zhou Caicun and Li Wei's team's participation in the Chinese study. Specific appointments, prescriptions and drug supply require confirmation.
Published research and clinical information can inform hospital selection; specific doctors, drug availability, international clinic charges and appointment dates are subject to confirmation by the hospital.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
You do not need to arrange new tests yourself for an initial consultation.
Costs, potential benefit and further treatment deserve specific answers before departure.
A single-arm study cannot establish that. Compare options in light of brain metastases, resistance mechanisms and tolerance. TRUST-I cannot guarantee efficacy after repotrectinib failure.
Treatment usually continues until progression or intolerance, with regular follow-up. Do not stop or change doses yourself. Liver function, ECG and lung risks still require monitoring.
Compare your local self-funded bill, Shanghai team availability, actual supply and long-term follow-up costs together. A hospital's published “patient-supplied” price is not a confirmed international patient quote and cannot guarantee savings.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
Portraits and hospital images come from the cited public sources or existing project assets. Public accessibility does not constitute a commercial image licence.